Competition Bureau closes two investigations into pharmaceutical patent litigation settlements* Bureau proactively monitors settlements between drug manufacturers to identify potentially illegal agreements The investigations were launched as a result of the Bureau’s proactive monitoring of agreements between branded and generic drug
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.